The synergistic impact of quinacrine on cell cycle and anti-invasiveness behaviors of doxorubicin in MDA-MB-231 breast cancer cells. (June 2019)

• Record Type: Journal Article
• Authors: Sabzichi, Mehdi; Ramezani, Mina; Mohammadian, Jamal; Ghorbani, Marjan; Mardomi, Alireza; Najafipour, Farzad; Mehdizadeh, Amir
• Is Part Of: Process biochemistry. Volume 81(2019)
• Page Start: 175
• Page End: 181
• Publication Date: 2019-06
• Subjects: Quinacrine -- Doxorubicin -- MDA-MB-231 -- Apoptosis -- Tumor migration; Biochemical engineering -- Periodicals; Biotechnology -- Periodicals; Biochemistry -- periodicals; Biotechnology -- periodicals; Chemical Engineering -- periodicals; Génie biochimique -- Périodiques; Biotechnologie -- Périodiques; Biochemical engineering; Biotechnology; Periodicals; 660.63
• DOI: 10.1016/j.procbio.2019.03.007
• Languages: English
• ISSNs: 1359-5113

Abstract

Graphical abstract: Highlights: Quinacrine has been recently reported as an anticancer agent. Quinacrine showed synergistic effect with doxorubicin by apoptosis induction. Quinacrine reduced cell growth and tumor migration and induced apoptosis and cell cycle arrest in MDA-MB 231 cell line. Quinacrine and doxorubicin combination therapy was suggested as an efficient approach for cancer treatment. Abstract: Combination therapy with a new and active component has been illustrated as a strategy in breast cancer treatment versus the conventional methods. Therefore, the current research investigated the role of quinacrine (QC) in enhancing the efficacy of doxorubicin (DOX) in MDA-MB-231 cancer cells. Anti-proliferation effect of co-administration of QC and DOX was examined using MTT assay and DAPI staining analysis. FACS techniques were performed to identify the molecular mechanisms of apoptosis and cell cycle progression. Moreover, the transwell migration assay was applied to measure the role of QC in the invasiveness of MDA-MB-231cells; the results showed that by applying QC along with DOX, the migration rate of cancer cells decreased significantly (2.41 fold; p < 0.5). The IC50 values were 1.2 ± 0.1 and 4.4 ± 0.4 μM for DOX and QC, respectively. The population of apoptotic cells was increased from 35 ± 2% to 40 ± 4% (p < 0.05) under treatment with DOX and QC. QC triggered mRNA level of pro-apoptotic marker Bax, and decreased anti-oxidant marker Nrf2 and anti-apoptotic marker bcl-xl, cyclin-B1 expression in MDA-MB-231cells. We found the combination therapy with DOX and QC a novel therapeutic approach that could enhance the efficacy of chemotherapy.